util
antibacteri
manag
acut
exacerb
chronic
bronchiti
aecb
relat
lung
patholog
chronic
obstruct
pulmonari
diseas
copd
debat
decad
data
present
articl
document
expens
antimicrobi
may
favor
aecb
treatment
prevent
advers
outcom
patient
name
antimicrobi
failur
hospit
identifi
patientspecif
variabl
may
lead
treatment
failur
includ
rightor
leftsid
heart
failur
exacerbationsyear
risk
factor
hospit
includ
age
year
sever
pulmonari
nonpulmonari
dysfunct
howev
risk
factor
never
formal
valid
prospect
random
trial
drugresist
organ
document
caus
antimicrobi
failur
hospit
howev
data
need
grow
area
report
chronic
obstruct
pulmonari
diseas
copd
fourth
lead
caus
death
us
estim
show
copd
result
million
offic
visit
hospit
annual
cost
associ
treatment
acut
exacerb
chronic
bronchiti
aecb
excess
billionyear
valu
goal
treatment
aecb
prompt
resolut
symptom
minim
failur
rate
organ
implic
caus
exacerb
base
sever
diseas
nontyp
haemophilu
influenza
moraxella
catarrhali
streptococcu
pneumonia
staphylococcu
aureu
virus
rhinovirus
influenza
b
viru
parainfluenza
coronaviru
herp
simplex
viru
respiratori
syncyti
viru
adenoviru
gramneg
pathogen
includ
pseudomona
aeruginosa
recent
year
atyp
pathogen
mycoplasma
pneumonia
chlamydia
pneumonia
report
investig
aecb
three
bacteri
pathogen
h
influenza
pneumonia
catarrhali
estim
account
episod
aecb
one
report
gramneg
pathogen
recov
less
commonli
bronchial
secret
patient
mild
moder
lung
dysfunct
aecb
howev
organ
indic
particularli
sever
impair
lung
function
forc
expiratori
volum
second
fev
valu
predict
viral
caus
aecb
estim
caus
exacerb
common
pathway
viral
pathogenesi
disrupt
respiratori
mucal
defens
allow
bacteria
attach
damag
epitheli
cell
patient
aecb
chronic
chlamydia
pneumonia
infect
shown
occur
patient
copd
one
report
c
pneumonia
determin
two
three
method
name
serum
antibodi
c
pneumonia
sputum
immunoglobulin
antibodi
c
pneumonia
polymeras
chain
reaction
sputum
c
pneumonia
dna
incid
sever
copd
mild
moder
copd
final
atyp
bacteria
precipit
bronchial
exacerb
current
question
regard
use
antibacteri
treatment
aecb
whether
aecb
pathophysiolog
similar
whether
antibacteri
use
treat
aecb
prevent
hospit
associ
morbid
mortal
furthermor
patient
requir
hospit
aecb
treatment
patientspecif
variabl
antibacterialresist
pathogen
viciou
cycl
infect
inflamm
injuri
promot
infect
propos
contribut
repeat
episod
infect
progress
loss
lung
function
remain
controversi
use
antibacteri
treatment
aecb
consider
debat
sinc
earli
placebocontrol
antibacteri
trial
condit
shown
posit
result
antibacteri
shown
moder
result
favor
antibacteri
certainli
econom
variabl
enter
decisionmak
process
select
antibacteri
aecb
discuss
investig
use
older
agent
low
perdos
cost
may
turn
increas
total
cost
treat
condit
offic
visit
noncompli
treatment
failur
advers
event
landmark
studi
report
anthonisen
et
al
studi
patient
diagnosi
aecb
copd
random
antibacteri
therapi
placebo
treatment
chronic
bronchiti
exacerb
upon
subsequ
exacerb
patient
enrol
studi
cross
arm
studi
antibacteri
use
trial
includ
cotrimoxazol
trimethoprimsulfamethoxazol
amoxicillin
amoxycillin
doxycyclin
standard
dose
patient
stratifi
studi
sever
exacerb
base
clinic
criteria
result
demonstr
success
rate
antibacterialtr
exacerb
time
higher
placebotr
arm
import
outcom
standpoint
placebotr
patient
experienc
deterior
condit
compar
antibacterialtr
arm
addit
differ
success
rate
antibacteri
arm
placebo
arm
greatest
patient
sever
diseas
type
ii
deterior
twice
much
placebo
compar
antibacteri
author
present
interpret
studi
result
comparison
previous
publish
aecb
antibacteri
trial
result
saint
et
al
publish
result
metaanalysi
nine
random
placebocontrol
antibacteri
trial
demonstr
small
statist
signific
benefit
use
antibacteri
treatment
aecb
current
numer
antibacteri
approv
treatment
aecb
previou
studi
antibacteri
aecb
account
differ
diseas
sever
among
patient
addit
sever
random
control
clinic
trial
investig
use
antibacteri
aecb
perform
earli
could
account
current
rate
antimicrobi
resist
util
bronchial
specimen
cultur
question
antibacteri
select
aecb
often
empir
destach
et
al
publish
retrospect
review
outpati
treat
aecb
pulmonologist
categor
antibacteri
use
treat
patient
aecb
initi
second
third
present
separ
week
correspondingli
antibacteri
categor
firstlin
amoxicillin
cotrimoxazol
tetracyclin
erythromycin
secondlin
cefradin
cefuroxim
cefaclor
cefprozil
thirdlin
amoxicillin
clavulan
acid
azithromycin
ciprofloxacin
antibacteri
failur
defin
failur
patient
respond
initi
antibacteri
requir
antibacteri
within
week
hospit
rate
gather
record
patient
hospit
within
week
initi
outpati
treatment
aecb
econom
variabl
time
aecb
interv
also
captur
medic
record
indic
approxim
patient
receiv
firstlin
antibacteri
first
outpati
visit
twentythre
percent
patient
given
secondlin
antibacteri
second
visit
switch
thirdlin
agent
condit
requir
third
visit
data
analysi
reveal
patient
treat
fail
respond
within
week
treatment
initi
patient
receiv
firstlin
agent
fail
respond
significantli
often
receiv
thirdlin
antibacteri
vs
patient
receiv
firstlin
antibacteri
hospit
significantli
often
within
week
outpati
treatment
given
thirdlin
agent
vs
final
use
thirdlin
antibacteri
associ
significantli
longer
time
interv
exacerb
compar
firstlin
secondlin
antibacteri
vs
week
statist
insignific
trend
toward
lower
mean
total
cost
aecb
treatment
use
thirdlin
agent
although
pharmaci
cost
alon
significantli
lower
firstlin
antibacteri
first
studi
document
possibl
differ
patient
base
antibacteri
prescrib
adam
et
al
document
studi
patient
relaps
significantli
often
given
antibacteri
compar
patient
receiv
antibacteri
addit
studi
also
document
highest
relaps
rate
patient
receiv
amoxicillin
therefor
two
studi
suggest
choic
certain
antibacteri
may
decreas
relaps
rate
hospit
associ
high
cost
subsequ
destach
et
al
studi
grossman
publish
review
treatment
aecb
articl
present
evid
treatment
success
failur
may
base
specif
patient
variabl
patientspecif
variabl
identifi
includ
cardiopulmonari
diseas
number
exacerbationsyear
cardiopulmonari
diseas
import
includ
rightor
leftsid
heart
failur
appear
studi
patient
four
exacerbationsyear
may
risk
antibacteri
failur
may
requir
thirdlin
antibacteri
name
azithromycin
amoxicillin
clavulan
acid
ciprofloxacin
addit
identifi
risk
factor
place
patient
increas
risk
hospit
acut
exacerb
eg
age
year
final
significantli
compromis
lung
function
sever
nonpulmonari
dysfunct
place
patient
increas
risk
hospit
articl
grossman
offer
propos
classif
patient
suggest
treatment
option
patient
acut
exacerb
chronic
bronchiti
howev
import
realiz
none
patientspecif
factor
prospect
determin
present
increas
risk
antibacteri
failur
prevent
hospit
inde
patient
sever
exacerb
type
anthonison
et
al
like
experi
benefit
antibacteri
compar
patient
less
sever
exacerb
addit
studi
date
document
whether
risk
hospit
relat
preval
resist
pathogen
need
determin
major
impact
prescript
costli
antibacteri
patient
sever
lung
dysfunct
year
sever
studi
present
th
intersci
confer
antimicrobi
agent
chemotherapi
icaac
meet
ball
et
al
present
abstract
compar
gemifloxacin
new
investig
quinolon
clarithromycin
studi
doubleblind
random
trial
patient
aecb
follow
week
enrol
patient
receiv
gemifloxacin
aecb
treatment
significantli
fewer
relaps
compar
patient
receiv
clarithromycin
success
compar
p
addit
gemifloxacin
recipi
compar
clarithromycin
recipi
requir
hospit
p
differ
treatment
group
may
relat
isol
haemophilu
influenza
studi
necessari
confirm
result
niederman
et
al
present
abstract
compar
antibacteri
treatment
interv
patient
aecb
receiv
antimicrobi
therapi
patient
divid
receiv
n
macrolid
n
quinolon
n
prescrib
physician
document
antimicrobi
use
treat
relaps
signific
differ
treatment
interv
patient
receiv
quinolon
compar
group
day
quinolon
macrolid
respect
p
research
describ
point
need
evalu
effect
exacerb
sever
make
appropri
choic
antibacteri
treatment
aecb
certainli
infectionfre
interv
may
appropri
use
compar
differ
antibacteri
patient
popul
anuezto
et
al
written
editori
outlin
protocol
test
whether
infectionfre
interv
valid
outcom
measur
patient
aecb
choic
antibacteri
treatment
aecb
episod
remain
controversi
see
tabl
research
need
gather
whether
newer
antimicrobi
prevent
treatment
failur
hospit
greater
extent
older
antimicrobi
final
newer
antimicrobi
posit
effect
outcom
better
coverag
resist
organ
may
caus
exacerb
investig
whether
resist
organ
caus
aecb
frequent
sensit
organ
determin
whether
resist
factor
outcom
aecb
would
interest
treat
patient
tabl
treatment
acut
exacerb
chronic
bronchiti
accord
classif
reproduc
grossman
permiss
classif
diseas
characterist
treatment
simpl
chronic
bronchiti
fev
predict
sputum
volum
purul
aminopenicillin
erythromycin
doxycyclin
cotrimoxazol
trimethoprimsulfamethoxazol
complic
chronic
bronchiti
fev
predict
age
year
exacerbationsyear
signific
comorbid
quinolon
inhibitor
second
gener
macrolid
second
third
gener
cefalosporin
forc
expiratori
volum
second
increas
